ZOONO GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.081 AUD | -1.22% |
|
-13.83% | +84.09% |
| Mar. 26 | Evolution Capital, OSY Group to Underwrite Zoono Group's AU$2.9 Million Rights Issue | MT |
| Mar. 19 | Zoono Group Says Unaware of Any Information for Share Price Fluctuation | MT |
| Sales 2022 | 9.02M 5.3M 8.28M | Sales 2023 | 3.34M 1.96M 3.06M | Capitalization | 7.83M 4.61M 7.19M |
|---|---|---|---|---|---|
| Net income 2022 | -11M -6.47M -10.1M | Net income 2023 | - 0 0 | EV / Sales 2022 | 2.27 x |
| Net cash position 2022 | 2.55M 1.5M 2.34M | Net Debt 2023 | 119K 69.76K 109K | EV / Sales 2023 | 2.38 x |
| P/E ratio 2022 |
-2.01
x | P/E ratio 2023 |
-19.6
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 33.27% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.22% | ||
| 1 week | -13.83% | ||
| Current month | -32.50% | ||
| 1 month | +62.00% | ||
| 3 months | +55.77% | ||
| 6 months | +92.86% | ||
| Current year | +84.09% |
1 week
0.08
0.10
1 month
0.050.13
Current year
0.030.13
1 year
0.030.13
3 years
0.031.07
5 years
0.033.29
10 years
0.033.29
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Hyslop
CEO | Chief Executive Officer | - | - |
Paul Ravlich
DFI | Director of Finance/CFO | - | 17-04-30 |
Lew MacKinnon
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Clarke
BRD | Director/Board Member | 69 | 17-04-25 |
Elissa Hansen
BRD | Director/Board Member | 51 | 15-10-08 |
Paul Hyslop
CEO | Chief Executive Officer | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 0.081 | -1.22% | 34,149 |
| 24-04-11 | 0.082 | -2.38% | 28,682 |
| 24-04-10 | 0.084 | -16.00% | 67,139 |
| 24-04-09 | 0.1 | +6.38% | 117,690 |
Delayed Quote Australian S.E., April 15, 2024 at 01:36 am EDT
More quotes
Zoono Group Limited is an Australia-based global biotech company that develops, manufactures and distributes a suite of antimicrobial solutions in multiple countries. The Company produces sprays, wipes and foams suited for skin care, surface sanitizers and mold remediation treatments. Its products are based on the ZOONO molecule, an antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mold. The Company markets its products in various countries, including Australasia, Asia, United States, India, United Kingdom and Europe. Its subsidiaries include Zoono Group Limited (NZ), Zoono Limited, Zoono Holdings Limited (UK), Zoono EU Limited, Zoono (Shanghai) Biotech Co. Limited, Zoono Holdings USA LLC and Zoono South Africa (Pty) Ltd.
Sector
Personal Products
Calendar
2024-08-21
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +84.09% | 11.18M | |
| +6.63% | 366B | |
| -1.47% | 118B | |
| +8.48% | 70.83B | |
| -16.61% | 61.75B | |
| -6.44% | 49.2B | |
| -11.75% | 36.63B | |
| -1.36% | 31.93B | |
| -0.36% | 16.14B | |
| +4.07% | 14.42B |
- Stock Market
- Equities
- ZNO Stock
